extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md

@@ -27,6 +27,12 @@ This is not an American problem alone. The American diet and lifestyle are sprea
 
 The four major risk factors behind the highest burden of noncommunicable disease -- tobacco use, harmful use of alcohol, unhealthy diets, and physical inactivity -- are all lifestyle factors that simple interventions could address. The gap between what science knows works (lifestyle modification) and what the system delivers (pharmaceutical symptom management) represents one of the largest misalignments in the modern economy.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+
+GLP-1s may function as a pharmacological counter to engineered food addiction. The population-level obesity decline (39.9% to 37.0%) coinciding with 12.4% adult GLP-1 adoption suggests pharmaceutical intervention can partially offset the metabolic consequences of engineered hyperpalatable foods, though this addresses symptoms rather than root causes of the food environment.
+
 ---
 
 Relevant Notes:

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -23,6 +23,18 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+
+The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
+
+
+### Additional Evidence (challenge)
+*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-15*
+
+Sarcopenic obesity risk from muscle loss + discontinuation may create NEW healthcare costs (falls, fractures, disability) that offset cardiovascular and metabolic savings, particularly in the Medicare-age population. If elderly patients experience functional decline from sarcopenia, they may require MORE healthcare utilization, directly challenging the cost-savings thesis. The weight cycling mechanism (muscle loss → discontinuation → fat regain without muscle regain) makes this the modal outcome given 64.8% one-year discontinuation rates.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
 
 No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-15*
+
+The discontinuation problem is compounded by body composition effects: patients who stop GLP-1s regain fat preferentially while muscle is NOT regained, creating worse body composition than baseline. This transforms discontinuation from a simple loss of metabolic benefit into an active harm through sarcopenic obesity progression, especially in elderly populations already experiencing 12-16% age-related muscle loss.
+
 ---
 
 Relevant Notes:

domains/health/the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md

@@ -31,6 +31,12 @@ Since specialization and value form an autocatalytic feedback loop where each am
 
 The Commonwealth Fund's 2024 international comparison demonstrates this transition empirically across 10 developed nations. All countries compared (Australia, Canada, France, Germany, Netherlands, New Zealand, Sweden, Switzerland, UK, US) have eliminated material scarcity in healthcare — all possess advanced clinical capabilities and universal or near-universal access infrastructure. Yet health outcomes vary dramatically. The US spends >16% of GDP (highest by far) with worst outcomes, while top performers (Australia, Netherlands) spend the lowest percentage of GDP. The differentiator is not clinical capability (US ranks 2nd in care process quality) but access structures and equity — social determinants. This proves that among developed nations with sufficient material resources, social disadvantage (who gets care, discrimination, equity barriers) drives outcomes more powerfully than clinical quality or spending volume.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+
+GLP-1 access inequality demonstrates the epidemiological transition in action: the intervention addresses metabolic disease (post-transition health problem) but access stratifies by wealth and insurance status (social disadvantage), potentially widening health inequalities even as population-level outcomes improve. The WHO's emphasis on 'multisectoral action' and 'healthier environments' acknowledges that pharmaceutical solutions alone cannot address socially-determined health outcomes.
+
 ---
 
 Relevant Notes:

domains/internet-finance/MetaDAO is the futarchy launchpad on Solana where projects raise capital through unruggable ICOs governed by conditional markets creating the first platform for ownership coins at scale.md

@@ -97,6 +97,12 @@ MetaDAO ICO platform processed 8 projects from April 2025 to January 2026, raisi
 
 MetaDAO Q3 2024 roadmap prioritized launching a market-based grants product as the primary objective, with specific targets to launch 5 organizations and process 8 proposals through the product. This represents an expansion from pure ICO functionality to grants decision-making, demonstrating futarchy's application to capital allocation beyond fundraising.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-04-09-blockworks-ranger-ico-metadao-reset]] | Added: 2026-03-15*
+
+Ranger Finance ICO completed in April 2025, adding ~$9.1M to total Assets Under Futarchy, bringing the total to $57.3M across 10 launched projects. This represents continued momentum in futarchy-governed capital formation, with Ranger being a leveraged trading platform on Solana. The article also notes MetaDAO was 'considering strategic changes to its platform model' around this time, though details were not specified.
+
 ---
 
 Relevant Notes:

entities/entertainment/claynosaurz.md

@@ -22,6 +22,8 @@ Community-driven animated IP founded by former VFX artists from Sony Pictures, A
 
 - **2025-06-02** — Announced 39-episode × 7-minute CG-animated series co-production with Mediawan Kids & Family, targeting kids 6-12. Distribution strategy: YouTube premiere followed by traditional TV licensing. Community involvement includes sharing storyboards, scripts, and featuring holders' collectibles in episodes. 450M+ views, 200M+ impressions, 530K+ subscribers at announcement.
 
+- **2025-06-01** — Announced partnership with Mediawan Kids & Family to produce 39 x 7-minute animated series, produced by Method Animation, launching on YouTube first then selling to TV/streaming. Described as 'first time a digital collectible brand is expanded into a TV series.' Creative team includes artists from Illumination, DreamWorks, Sony, Disney, and Ubisoft.
+- **2025-06-02** — Announced co-production deal with Mediawan Kids & Family (Method Animation) for 39 x 7-minute animated series. YouTube-first distribution strategy, retaining creative control and IP ownership through co-production structure rather than licensing. Deal presented at Annecy International Animation Festival.
 ## Relationship to KB
 
 - Implements [[fanchise management is a stack of increasing fan engagement from content extensions through co-creation and co-ownership]] through specific co-creation mechanisms

entities/internet-finance/futardio.md

@@ -49,6 +49,7 @@ MetaDAO's token launch platform. Implements "unruggable ICOs" — permissionless
 - **2026-03-05** — [[insert-coin-labs-futardio-fundraise]] launched for Web3 gaming studio (failed, $2,508 / $50K = 5% of target)
 - **2026-03-05** — [[git3-futardio-fundraise]] failed: Git3 raised $28,266 of $100K target (28.3%) before entering refunding status, demonstrating market filtering even with live MVP
 - **2024-06-14** — [[futardio-fund-rug-bounty-program]] passed: Approved $5K USDC funding for RugBounty.xyz platform development to incentivize community recovery from rug pulls
+- **2024-08-28** — MetaDAO proposal to develop futardio as memecoin launchpad with futarchy governance failed. Proposal would have allocated $100k grant over 6 months to development team. Key features: percentage of each new token supply allocated to futarchy DAO, points-to-token conversion within 180 days, revenue distribution to $FUTA holders, immutable deployment on IPFS/Arweave. Proposal rejected by market, suggesting reputational risks outweighed adoption benefits.
 ## Competitive Position
 - **Unique mechanism**: Only launch platform with futarchy-governed accountability and treasury return guarantees
 - **vs pump.fun**: pump.fun is memecoin launch (zero accountability, pure speculation). Futardio is ownership coin launch (futarchy governance, treasury enforcement). Different categories despite both being "launch platforms."

inbox/archive/.extraction-debug/2025-06-01-cell-med-glp1-societal-implications-obesity.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md:set_created:2026-03-15",
+      "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md:set_created:2026-03-15"
+    ],
+    "rejections": [
+      "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md:missing_attribution_extractor",
+      "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-15"
+}

inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-risk.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-risk.md:set_created:2026-03-15"
+    ],
+    "rejections": [
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-risk.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-15"
+}

inbox/archive/2025-04-09-blockworks-ranger-ico-metadao-reset.md

@@ -7,9 +7,13 @@ date: 2025-04-09
 domain: internet-finance
 secondary_domains: []
 format: article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [metadao, ranger-finance, ICO, assets-under-futarchy, ownership-coins]
+processed_by: rio
+processed_date: 2026-03-15
+enrichments_applied: ["MetaDAO is the futarchy launchpad on Solana where projects raise capital through unruggable ICOs governed by conditional markets creating the first platform for ownership coins at scale.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -43,3 +47,11 @@ tags: [metadao, ranger-finance, ICO, assets-under-futarchy, ownership-coins]
 PRIMARY CONNECTION: [[MetaDAO is the futarchy launchpad on Solana where projects raise capital through unruggable ICOs governed by conditional markets creating the first platform for ownership coins at scale]]
 WHY ARCHIVED: Latest AUF figure ($57.3M) and "strategic reset" signal worth tracking
 EXTRACTION HINT: The AUF metric is data for updating existing claims; the "strategic reset" needs follow-up investigation
+
+
+## Key Facts
+- MetaDAO total Assets Under Futarchy reached $57.3M as of April 9, 2025
+- Ranger Finance ICO added approximately $9.1M to MetaDAO's AUF
+- MetaDAO has launched 10 projects to date as of April 2025
+- MetaDAO ICO sales use a 4-day deposit period with USDC
+- MetaDAO was considering a 'strategic reset' to its platform model in April 2025

inbox/archive/2025-06-01-cell-med-glp1-societal-implications-obesity.md

@@ -7,9 +7,13 @@ date: 2025-06-01
 domain: health
 secondary_domains: [entertainment, internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, obesity, societal-impact, equity, food-systems, population-health, sustainability]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md", "the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -52,3 +56,11 @@ EXTRACTION HINT: Focus on both the population-level effect AND the equity concer
 
 flagged_for_clay: ["GLP-1 adoption is reshaping cultural narratives around obesity, body image, and pharmaceutical solutions to behavioral problems — connects to health narrative infrastructure"]
 flagged_for_rio: ["GLP-1 equity gap creates investment opportunity in access-focused models that serve underserved populations — potential Living Capital thesis"]
+
+
+## Key Facts
+- October 2025 Gallup poll: 12.4% of US adults taking GLP-1 for weight loss (30M+ people)
+- US obesity prevalence: 39.9% (2022) → 37.0% (2025), representing 7.6M fewer obese Americans
+- WHO issued conditional recommendations for GLP-1s in December 2025
+- Obesity costs US $400B+ annually
+- WHO three-pillar approach: healthier environments (population policy), protect high-risk individuals, person-centered care

inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md

@@ -7,9 +7,13 @@ date: 2025-07-01
 domain: health
 secondary_domains: []
 format: review
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -50,3 +54,12 @@ WHY ARCHIVED: Counter-evidence to the GLP-1 benefit thesis — sarcopenia risk m
 EXTRACTION HINT: The intersection of muscle loss + high discontinuation rates is the key risk — evaluate as a challenge to the cost-savings thesis, not just a clinical side effect
 
 flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to spaceflight muscle atrophy — different mechanism but similar functional consequences"]
+
+
+## Key Facts
+- Natural aging reduces skeletal muscle mass by 12-16%
+- Sarcopenic obesity prevalence in older adults: 10-20%
+- 15-40% of total weight lost on GLP-1s is lean body mass (some analyses suggest up to 60%)
+- Mitigation strategies include high protein diet + resistance training, but adherence is low
+- No pharmacological solution to GLP-1-induced muscle loss currently exists
+- Next-generation GLP-1 compounds aim to improve 'quality of weight loss' by preserving muscle (ADA)